Instant analgesic effect of radial extracorporeal shock wave therapy on primary dysmenorrhoea according to functional magnetic resonance imaging: study protocol for a randomised placebo-controlled trial.

Publication date: Feb 11, 2020

Primary dysmenorrhoea (PDM) is defined as a series of pain-dominated symptoms during and after menstruation without organic lesions. Nonsteroidal anti-inflammatory drugs and oral contraceptives are usually recommended as first-line therapy for the clinical treatment of PDM, but their widespread long-term application is controversial. Radial extracorporeal shock wave therapy (rESWT) has been widely applied in musculoskeletal rehabilitation because of its secure and noninvasive characteristics and its confirmed effect in improving pain symptoms. This research seeks to explore the efficacy of rESWT for PDM and the changes in brain function of patients with PDM.

This clinical research will be a randomised, blind, sham-controlled trial. Thirty-six patients with PDM will be randomly divided into the rESWT group (n?=?18) and the sham rESWT group (n?=?18). In the rESWT group, treatment will be applied once within 48?h of menstruation at six abdominal myofascial trigger points. The sham rESWT group will receive sham shockwave therapy on the same sites but without energy input. Other dysmenorrhoea-related treatments in both groups will be limited. The main indicators include the short form of the McGill Pain Questionnaire and the Cox Menstrual Symptom Scale. The secondary indicators include the Zung Self-rating Anxiety Scale and Self-rating Depression Scale and functional magnetic resonance imaging (fMRI) changes in brain regions. Results will be evaluated at the screening, at baseline, and before and after treatment, and adverse treatments will be examined. Inter- and intragroup analyses will be performed.

This randomised controlled study is designed to explore the immediate efficacy of rESWT for PDM. After rESWT treatment, PDM symptom tests and pain tests, as well as fMRI data, will be investigated for the potential connections between immediate neuroanalgesic mechanisms, which are associated with pain and brain networks. The main results will be used to assess the efficacy of rESWT, and secondary results will focus on improving the neurobiological understanding of disease treatment.

China Clinical Trial Register, ChiCTR1900020678. Registered on 13 January 2019.

Open Access PDF

Liu, S., Wang, L., and Yang, J. Instant analgesic effect of radial extracorporeal shock wave therapy on primary dysmenorrhoea according to functional magnetic resonance imaging: study protocol for a randomised placebo-controlled trial. 21019. 2020 Trials (21):1.

Concepts Keywords
Analgesic RESWT
Brain Pain
China Myofascial trigger points
Dysmenorrhoea Oral contraceptives
Energy Medicine
Extracorporeal Health
FMRI Magnetic resonance
Menstruation Therapy
Musculoskeletal Extracorporeal shockwave therapy
Neurobiological Pain
Oral Contraceptives Placebo
Pain Magnetic resonance imaging
Placebo
Protocol
Shock Wave
Symptom
Trigger Points

Semantics

Type Source Name
disease MESH shock
disease MESH Anxiety
disease MESH Depression
disease MESH menstrual pain
disease MESH growth
disease MESH plantar fasciitis
disease MESH musculoskeletal diseases
drug DRUGBANK Trestolone
drug DRUGBANK Ibuprofen
pathway REACTOME Metabolism
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Naproxen
drug DRUGBANK Sodium lauryl sulfate
disease MESH Allergy
disease MESH Contraindications
disease MESH claustrophobia
disease MESH visual
disease MESH backaches
disease MESH anxiety disorder
drug DRUGBANK Coenzyme M
disease MESH carpal tunnel syndrome
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH open angle glaucoma
disease MESH abnormalities

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *